Financial Results for the Fiscal Year Ended March 31, 2014



May 8, 2014 Exchange where listed: TSE

Name of listed company : TERUMO CORPORATION (URL http://www.terumo.com/)

Company code number : 45

Representative: Yutaro Shintaku, President and Representative Director

Please address all communications to : Masayuki Maruta, General Manager, Corporate Communication Dept.

Phone : +81 / 3-6742-8550 Adoption of U.S. accounting standards [Yes/No]: No

Consolidated Financial Highlights for the Year Ended March 2014 (From April 1, 2013 to March 31, 2014)

(1) Consolidated financial results

(Notes: The amounts shown below ignore values of less than a million yen)

	Net sales		Operating income		Ordinary income			Net income		
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)		%	(Millions of yen)	%	
Year ended March, 2014	467,359	16.2	65,288	22.7	63,802	24.2		34,096	(27.5)	
Year ended March, 2013	402,294	4.0	53,216	(15.6)	51,376	(13.2)		47,014	94.5	

(Notes) Comprehensive income: March 2014: 71,166million yen (24.1%) March 2013: 93,735million yen (294.9%)

	Net income per share	Net income per share, fully diluted	Net income per stockholders' equity	Ordinary income per total assets	Operating income per Net sales
	(Yen)	(Yen)	%	%	%
Year ended March, 2014	89.78	89.78	7.3	8.0	14.0
Year ended March, 2013	123.80	_	11.9	7.0	13.2

 $(Notes) \ Equity in earnings of affiliates: \quad March \ 2014: \ 132 million \ yen \quad March \ 2013: \ 176 million \ yen$

Terumo Corporation split each share of common stock into two shares effective on 1st April 2014,

Net income per share and Net income per share, fully diluted have been restated.

(2) Consolidated financial position

	Total assets	Net assets	Equity ratio	Net assets per share
	(Millions of yen)	(Millions of yen)	%	(Yen)
As at March 31, 2014	832,814	496,245	59.6	1,306.72
As at March 31, 2013	771,032	437,909	56.7	1,152.21

(Notes) Shareholders' equity: March 31, 2014: 496,225 million yen March 31, 2013: 437,557 million yen Terumo Corporation split each share of common stock into two shares effective on 1st April 2014, Net asset per share have been restated.

(3) Consolidated statements of cash flows

	Cash flows from operating activities		Cash flows from financing activities	Cash and cash equivalents, end of period	
	(Millions of yen)	(Millions of yen)	(Millions of yen)	(Millions of yen)	
Year ended March, 2014	96,259	(52,744)	(31,785)	92,498	
Year ended March, 2013	50,270	(31,293)	(22,340)	75,165	

2. Dividends

	Cash dividends per share							
	at 1st half end	at fiscal year end	total					
	(Yen)	(Yen)	(Yen)					
Year ended March, 2013	22.00	22.00	44.00					
Year ended March, 2014	29.00	29.00	58.00					
Year ending March, 2015 (forecast)	14.50	14.50	29.00					

(Notes) Terumo Corporation split each share of common stock into two shares effective on 1st April 2014, and this forecast of Cash dividends per share is reflected this stock split.

3. Consolidated Forecast for the Year Ending March 2015 (From April 1, 2014 to March 31, 2015)

	Net sales		Operating income		Ordinary income		Net income		Net income per share	
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Yen)	
Half year ending September, 2014	236,000	4.4	28,000	(8.1)	27,000	(8.7)	16,000	(17.8)	42.13	
Year ending March, 2015	488,000	4.4	64,000	(2.0)	62,000	(2.8)	37,500	10.0	98.75	

(Notes) Assumed exchange rate in FY2014: $\,$ 1US\$=100yen, 1Euro=140yen

 $Terumo\ Corporation\ split\ each\ share\ of\ common\ stock\ into\ two\ share\ effective\ on\ 1st\ April\ 2014,$ and this forecast of Net income per share is reflected this stock split\ excluding\ treasury\ stock.

Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

4. Financial Statements

(1) Consolidated balance sheet

(Millions of yen)

(1) Consolidated balance sneet	As at March	21 2012	As at March 31	2014	Changes	ons or yen)
	Amount	31, 2013	Amount	, 2014	Amount	
(Assets)	Amount	%		%	rimount	%
I Current assets	286,9			37.3%	24,029	8.4%
Cash and deposits	78,2	01	95,618		17,417	
Notes and accounts receivable-trade	95,0	08	101,520		6,511	
Marchandise and finished goods	54,3	46	60,034		5,688	
Work in process	9,2	65	10,262		997	
Raw materials and supplies	21,5	68	23,668		2,100	
Deferred tax assets	11,2	58	12,340		1,082	
Other	18,5	28	8,933		(9,594)	
Allowance for doubtful accounts	(1,2	20)	(1,394)		(173)	
II Noncurrent assets	483,7	70 62.8%	520,332	62.5%	36,562	7.6%
1. Property, plant and equipment	144,8	24 18.8%	157,755	18.9%	12,930	8.9%
Buildings and structures	48,9	66	54,215		5,249	
Machinery, equipment and vehicles	46,3	66	43,916		(2,450)	
Land	21,8	27	21,757		(69)	
Lease assets	7	04	406		(297)	
Construction in progress	17,7	94	27,974		10,180	
Other	9,1	65	9,483		317	
2. Intangible assets	296,6	38.5%	304,756	36.7%	8,122	2.7%
Goodwill	149,3	22	154,161		4,838	
Customer-related assets	90,7	06	93,968		3,261	
Other	56,6	04	56,626		21	
3. Investments and other assets	42,3	11 5.5%	57,820	6.9%	15,509	36.7%
Investment securities	30,3	04	37,954		7,649	
Deferred tax assets	5,1	53	5,323		169	
Net defined benefit asset		-	2,573		2,573	
Other	6,8	52	11,969		5,116	
III Deferred assets	3	0.0%	1,496	0.2%	1,189	387.7%
Total assets	771,0	32 100.0%	832,814	100.0%	61,781	8.0%

(Millions of yen)

_		As at March 31	2019	As at March 31	2014	Changes	ons of yen)
		As at March 31 Amount	, 2015	As at Waren 31	, 2014	Amount	
/т :	abilities)	Amount	%	Amount	%	Amount	9/
I I	Current liabilities	115,844	15.0%	160,936	19.3%	45,092	38.9%
	Notes and accounts payable-trade	37,515		38,147		632	
	Short-term loans payable	18,046		260		(17,785)	
	Current portion of long-term loans payable	3,762		4,652		890	
	Lease obligations	277		225		(51)	
	Current portion of bonds	_		40,000		40,000	
	Income taxes payable	2,609		18,401		15,792	
	Deferred tax liabilities	35		94		59	
	Provision for bonuses	4,834		4,849		15	
	Provision for directors' bonuses	109		109		0	
	Notes and accounts payable-facilities	6,624		8,425		1,801	
	Asset retirement obligations	420		_		(420)	
	Other	41,611		45,769		4,158	
II	Noncurrent liabilities	217,278	28.2%	175,632	21.1%	(41,646)	(19.2%)
	Bonds payable	80,000		40,000		(40,000)	
	Long-term loans payable	78,712		76,769		(1,942)	
	Lease obligations	439		299		(139)	
	Deferred tax liabilities	49,659		47,795		(1,863)	
	Provision for retirement benefits	1,247		_		(1,247)	
	Net defined benefit liability	_		3,124		3,124	
	Provision for directors' retirement benefits	198		66		(132)	
	Asset retirement obligations	155		220		64	
	Other	6,865		7,354		489	
Tot	al liabilities	333,122	43.2%	336,568	40.4%	3,445	1.0%
Ι	Shareholders' equity	419,999	54.5%	444,396	53.4%	24,397	5.8%
	Capital stock	38,716		38,716		_	
	Capital surplus	52,103		52,103		_	
	Retained earnings	329,188		353,600		24,412	
	Treasury stock	(9)		(24)		(14)	
II	Accumulated other comprehensive income	17,557	2.3%	51,828	6.2%	34,270	195.2%
	Valuation difference on available-for-sale securities	7,458		11,269		3,811	
	Deferred gains or losses on hedges	_		(2)		(2)	
	Foreign currency translation adjustment	10,099		43,377		33,278	
	Remeasurements of defined benefit plans	_		(2,816)		(2,816)	
Ш	Subscription rights to shares	_	_	20	0.0%	20	_
IV	Minority interests	352	0.0%	_	_	(352)	_
Tot	cal net assets	437,909	56.8%	496,245	59.6%	58,335	13.3%
Tot	al liabilities, net assets	771,032	100.0%	832,814	100.0%	61,781	8.0%

(Millions of ven)

(2) Consolidated statement of income	<u> </u>							(Milli	ons of yen)
	For	the year e	nded	For	the year e	nded			
	M	arch 31, 20)13	M	arch 31, 20)14		Changes	
	Am	ount		Am	ount		Amo	ount	
			%			%			9/
I Net sales		402,294	100.0%		467,359	100.0%		65,065	16.2%
II Cost of sales		196,605	48.9%		225,348	48.2%		28,742	14.6%
Gross profit		205,688	51.1%		242,011	51.8%		36,323	17.7%
III Selling, general and administrative expenses		152,472	37.9%		176,722	37.8%		24,250	15.9%
Operating income		53,216	13.2%		65,288	14.0%		12,072	22.7%
IV Non-operating income									
Interest income	307			459			151		
Dividends income	284			338			54		
Royalty income	124			116			(7)		
Foreign exchange profit	1,257			3,250			1,992		
Equity in earnings of affiliates	176			132			(43)		
Other	1,009	3,160	0.8%	1,203	5,501	1.2%	193	2,341	74.1%
V Non-operating expenses									
Interest expenses	1,303			1,542			238		
Sales discounts	597			661			63		
Loss on disposal of inventories	677			836			158		
Other	2,421	5,000	1.2%	3,947	6,988	1.5%	1,526	1,988	39.8%
Ordinary income		51,376	12.8%		63,802	13.7%		12,425	24.2%
VI Extraordinary income									
Gain on sales of noncurrent assets	77			743			665		
Subsidy income	875			_			(875)		
Gain on transfer of business	892			666			(225)		
Settlement received	_	1,846	0.4%	6,000	7,410	1.5%	6,000	5,564	301.4%
VII Extraordinary expenses									
Loss on disposal of noncurrent assets	543			995			451		
Impairment loss	_			15,351			15,351		
Directors' retirement benefits	_			33			33		
Loss on liquidation of business	_			740			740		
Loss on system fault	_			1,185			1,185		
Loss on valuation of golf club memberships	3			_			(3)		
Environmental expenses	390	937	0.2%	_	18,305	3.9%	(390)	17,367	1,852.6%
Income before income taxes		52,285	13.0%		52,907	11.3%		622	1.2%
Income taxes-current	7,179			26,637			19,457		
Income taxes-deferred	(1,961)	5,218	1.3%	(7,856)	18,780	4.0%	(5,894)	13,562	259.9%
Income before minority interests		47,067	11.7%		34,126	7.3%		(12,940)	(27.5%
Minority interests in income		53	0.0%		30	0.0%		(22)	(41.9%
Net income		47,014	11.7%		34,096	7.3%		(12,918)	(27.5%)

(3) Consolidated statement of comprehensive income

(Millions of yen)

	March S	ear ended 31, 2013 punt	For the year ended March 31, 2014 Amount		
I Income before minority interests II Other comprehensive income	47,067		34,126		
Valuation difference on available-for-sale securities	7,510		3,811		
Deferred gains or losses on hedges	(1)		(2)		
Foreign currency translation adjustments Share of other comprehensive income of associates	39,157		33,234		
accounted for using equity method	2	46,668	(3)	37,039	
Comprehensive income		93,735		71,166	
Attributable to:					
Shareholders of Terumo Corporation		93,647		71,179	
Minority interests		87		(13)	

(4) Statement of changes in net assets

(4) Statement of changes in net assets					(Millions of ven)						
		Shareholders' equity									
Year ended March 2013	Capital stock	Capital surplus	Retained earnings	Treasury stock	Shareholders' equity total						
Beginning of period	38,716	52,103	290,529	(3)	381,345						
Changes during this fiscal year											
Dividends from surplus Net income Purchase of treasury stock			(8,354) 47,014	(5)	(8,354) 47,014 (5)						
Changes of items other than shareholders' equity (net)											
Total changes during this fiscal year	_	-	38,659	(5)	38,653						
Ending of period	38,716	52,103	329,188	(9)	419,999						

Year ended March 2013	Valuation difference on available-for-sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustments	Remeasurements of defined benefit plans	Accumulated other comprehensive income total	Subscription rights to shares	Minority interests	Net assets total
Beginning of period	(51)	1	(29,023)	-	(29,073)	-	264	352,537
IFRS Adjustment								
Changes during this fiscal year								
Dividends from surplus Net income Purchase of treasury stock								(8,354) 47,014 (5)
Changes of items other than shareholders' equity (net)	7,510	(1)	39,122	-	46,630	-	87	46,718
Total changes during this fiscal year	7,510	(1)	39,122	-	46,630	-	87	85,372
Pading of annial	7.459		10.000		17 557	_	950	427 909

					(Millions of yen)		
		Shareholders' equity					
Year ended March 2014	Capital stock	Capital surplus	Retained earnings	Treasury stock	Shareholders' equity total		
Beginning of period	38,716	52,103	329,188	(9)	419,999		
Changes during this fiscal year							
Dividends from surplus Net income			(9,683) 34,096		(9,683) 34,094		
Purchase of treasury stock Changes of items other than shareholders' equity (net)				(14)	(14)		
Total changes during this fiscal year	1	_	24,412	(14)	24,397		
Ending of period	38,716	52,103	353,600	(24)	444,396		

	Accumulated other comprehensive income							
Year ended March 2014	Valuation difference on available for sale securities	Deferred gains or losses on hedges	Foreign currency translation adjustments	Remeasurements of defined benefit plans	Accumulated other comprehensive income total	Subscription rights to shares	Minority interests	Net assets total
Beginning of period	7,458	-	10,099	-	17,557	-	352	437,909
IFRS Adjustment								
Changes during this fiscal year								
Dividends from surplus Net income								(9,683) 34,096
Purchase of treasury stock								(14)
Changes of items other than shareholders' equity (net)	3,811	(2)	33,278	(2,816)	34,270	20	(352)	33,938
Total changes during this fiscal year	3,811	(2)	33,278	(2,816)	34,270	20	(352)	58,335
Ending of period	11,269	(2)	43,377	(2,816)	51,828	20	-	496,245

(5) Consolidated statements of cash flows		(Millions of yer
	For the year ended	For the year ended
	March 31, 2013	March 31, 2014
	Amount	Amount
I Net cash provided by (used in) operating activities		
Income before income taxes	52,285	52,907
Depreciation and amortization	24,601	30,322
Impairment loss	_	15,351
Amortization of goodwill	7,952	9,559
Equity in (earnings) losses of affiliates	(176)	(132)
Increase(decrease) in provision for retirement benefits	(534)	
	(534)	(1,247)
Decrease (increase) in net defined benefit asset	_	(1,899)
Increase(decrease) in net defined benefit liability	_	1,506
Increase(decrease) in provision for directors' retirement benefits	(3)	(132)
Increase(decrease) in allowance for doubtful accounts	(96)	73
Increase(decrease) in provision for directors' bonuses	(18)	0
Interest and dividends income	(591)	(798)
Interest expenses	1,303	1,542
Foreign exchange losses (gains)	(2,976)	(3,210)
Subsidy income	(875)	_
Gain on transfer of business	(892)	(666)
Settlement received	_	(6,000)
Loss (gain) on sales of noncurrent assets	(77)	(743)
Loss (gain) on disposal of noncurrent assets	543	995
Payments cash contribution of securities to retirement benefit trust	949	(3,600)
Payments cash contribution of securities to retirement benefit trust Directors' retirement benefits	_	*-,
	_	33
Loss on liquidation of business	_	740
Loss on system fault	_	1,185
Loss on valuation of golf club memberships	3	_
Loss on environmental expenses	390	_
Decrease (increase) in notes and accounts receivable-trade	985	(506)
Decrease (increase) in inventories	(10,590)	(3,618)
Increase (decrease) in trade payable	3,925	(1,096)
Other, net	(78)	4,849
Subtotal	75,078	95,411
Interest and dividends income received	841	1,020
	(1,330)	(1,522)
Interest expenses paid		
Income taxes paid	(24,321)	(2,875)
Settlement package received	_	6,000
Payments for directors' retirement benefits	_	(33)
Loss on system fault paid	_	(943)
Payments for environmental expenses	_	(798)
Subsidy income received	0	
Net cash provided by (used in) operating activities	50,270	96,259
II Net cash provided by (used in) investment activities		
Payments into time deposits	(561)	(767)
Proceeds from withdrawal of time deposits	2,803	1,182
		(39,933)
Purchase of property, plant and equipment	(25,715)	
Proceeds from sales of property, plant and equipment	322	953
Purchase of intangible assets	(6,759)	(4,960)
Payments for performance to asset retirement obligations	(420)	(420)
Purchase of investment securities	(1,074)	(1,823)
Payments for transfer of business	_	(1,828)
Capital expenditure for subsidiary's equity	(956)	(374)
Purchase of stocks of subsidiaries and affiliates	_	(1,519)
Proceeds from transfer of business	1,372	1,815
Other, net	(306)	(5,069)
Net cash provided by (used in) investment activities	(31,293)	(52,744)
	ζ= -,=00/	, , , , , , , , , , , , , , , , , , ,
III Net cash provided by (used in) finacing activities		
Increase in short-term loans payable	1,264	253
Decrease in short-term loans payable	(1,278)	(4,055)
Net increase (decrease) in short-term loans payable	(42,000)	(18,000)
Proceeds from long-term loans payable	28,612	_
Repayments of financial lease obligations	(579)	(284)
Purchase of treasury stock	(5)	(14)
Cash dividends paid	(8,354)	(9,683)
Net cash provided by (used in) finacing activities	(22,340)	(31,785)
	4,735	5,603
IV Effect of exchange rate changes on cash and cash equivalents	·	
V Net increase(decrease) in cash and cash equivalents	1,371	17,332
	·	17,332 75,165

<Significant accounting policies in preparing the consolidated financial statements>

Changes in accounting policy

(Adoption of Accounting Standard for Retirement Benefits)

Concomitant with the Accounting Standard for Retirement Benefits (Accounting Standards Board of Japan (ASBJ) Statement No. 26 of May 17, 2012), and Guidance on Accounting Standard for Retirement Benefits (ASBJ Guidance No. 25. of May 17, 2012), the Company has applied these standards as of the fiscal year ending March 31, 2014. Under the new standard, pension assets are deducted from retirement benefit obligations and the net amount is recognized as liability for retirement benefits, and previously unrecognized actuarial gains and losses and unrecognized prior services costs are recorded as liability for retirement benefit.

In accordance with transitional accounting as stipulated in article 37 of the Accounting Standard for Retirement Benefits, the effect of the changes in accounting policies arising from initial application is recognized in accumulated adjustments for retirement benefit within the net asset section at the end of the fiscal year ending March 31, 2014. As a result, "Net defined benefit asset" and "Net defined benefit liability" on the consolidated balance sheet have increased by \$2,573 million and \$3,124 million each at the end of the fiscal year ending March 31, 2014, and accumulated other comprehensive income has decreased by \$2,816 million. Net asset per share has decreased by \$7.42.

<Subsequent Event>

The Company executed a stock split effective April 1, 2014, according to the resolution of the Board of Directors' meeting on February 4, 2014.

Details of the stock split are as follows:

1. Purpose of stock split

The stock split will be conducted with the aim of increasing the liquidity of the Company's stock and expanding its investor base by reducing the price of share-trading units.

2. Method of the stock split

Each share of common stock held by shareholders recorded on the register of shareholders as of March 31, 2014, was split into 2 shares.

3. Increase in the number of shares due to the stock split

Common stock 189,880,260 shares

Per share data have been restated, as appropriate, to reflect a two-for-one stock split effective April 1, 2013.

5. Segment Information

[Reportable Segments]

(Note) Main products belonging to each business segment

Business segments	Previous sub-segments	New sub-segments	Main products
	Disposable medical devices and medical electronics	General Hospital Products	Syringes, Needles, Blood collection tubes, Solution sets, I.V.catheters, Infusion pumps, Syringe pumps, etc.
General Hospital business	Pharmaceuticals Pharmaceutical and Nutrition I.V.		tical and Nutrition I.V.solutions, Nutritious food, CAPD systems, etc.
General Hospital business	-	D&D	Prefilled syringes, Pain management systems etc.
	Diabetes care products	DM and Consumer Healthcare	Blood glucose monitoring systems, Digital Thermometers, Blood pressure monitors, etc.
	Consumer Healthcare business	-	-
	Interventional systems	Interventional systems	Angiographic catheters, PTCA balloon catheters, Coronary stents
Cardiac and Vascular business	-	Neurovascular	Neuro interventional coils, etc.
Cardiac and Vascular business	Cardiovascular systems	CV Systems	Oxygenerators, Cardio-pulmonary bypass system, etc.
	Vascular grafts	tes DM and Consumer Healthcare Thermometers, E Isiness Interventional systems Angiographic cat Coronary stents Neurovascular Neuro intervention CV Systems Oxygenerators, C etc. Vascular graft Artificial vascula Blood bags, Auto	Artificial vascular grafts, Stent grafts
Blood Management business		-	Blood bags, Automated blood collection system, Therapeutic apheresis system, Cell expansion system, etc.

(Note) Changes in segments clasification

Sales and expenses related to home oxygen system business and home infusion pump business sold off in previous fiscal year and next generation implantable left ventricular assist system entered in strategic alliance in this fiscal year are allocated to "Adjustments."

As a result of this changes, compared to the previous classification, the segment income for the fiscal year ending March 31, 2013 has increased accordingly; General Hospital Business ¥366 million, Cardiac & Vascular Business ¥3,640 million, Blood Management Business ¥39 million. The segment income of "Adjustment" has decreased by ¥4,047 million.

(1) Fiscal year ended March 31, 2013

(Millions of yen)

	For the year ended								
		March 31, 2013							
	General Hospital Business	Cardiac & Vascular Business	Blood Management Business	Subtotal	Adjustment	Total			
Sales and operating income:									
Sales to customer	155,010	169,678	74,745	399,432	2,860	402,294			
Internal sales	_	_	_	_	_	_			
Sales total	151,010	169,678	74,745	399,432	2,862	402,294			
Segment income (Excl. Amortization)	23,647	29,049	13,817	66,513	243	66,756			
Segment income	23,647	27,281	2,004	52,972	243	53,216			
Segment income(%)(Excl. Amortization)	15.3	17.1	18.5	16.7	_	16.6			
Segment assets	168,316	219,296	308,322	695,935	75,097	771,032			
Others:									
Depreciation and amortization	7,765	5,890	10,476	24,132	468	24,601			
Amortization of goodwill	_	1,767	6,184	7,952	_	7,952			
Net increase of tangible and intangible noncurrent assets	12,794	12,868	6,564	32,226	935	33,162			

Notes:

- Segment income is adjusted to be consistent with operating income shown on the consolidated income statement.
- 2. Adjustment to segment income (loss), which amounted to 243 million yen, is the sum of 584 million yen for Inventories and (340) million yen for others.
- 3. Adjustment to segment assets, which amounted to 75,097 million yen, mainly includes investments in "Cash and deposit", "Investments securities", "Deferred tax assets" and assets of the Administrative Department.

(2) Fiscal year ended March 31, 2014

/a e			\
(Mill	ions	of ven)

(2) Fiscal year clided March 51, 2014					(WIIII)	ons of yen			
		For the year ended							
		March 31, 2014							
	General Hospital Business	Cardiac & Vascular Business	Blood Management Business	Subtotal	Adjustment	Total			
Sales and operating income:									
Sales to customer	164,089	210,558	92,743	467,391	(32)	467,359			
Internal sales	_	_	_	_	_	_			
Sales total	164,089	210,558	92,743	467,391	(32)	467,359			
Segment income (Excl. Amortization)	20,797	43,928	18,613	83,339	(1,740)	81,599			
Segment income	20,797	41,949	4,281	67,028	(1,740)	65,288			
Segment income(%)(Excl. Amortization)	12.7	20.9	20.1	17.8	_	17.5			
Segment assets	171,316	237,446	327,087	735,850	96,963	832,814			
Others:									
Depreciation and amortization	8,660	8,988	11,811	29,460	861	30,322			
Amortization of goodwill	_	1,979	7,580	9,559	_	9,559			
Net increase of tangible and intangible noncurrent assets	13,037	22,022	10,561	45,621	1,002	46,624			

Notes:

Sales

- 1. Segment income is adjusted to be consistent with operating income shown on the consolidated income statement.
- 2. Adjustment to segment income (loss), which amounted to (1,740) million yen, is the sum of (129) million yen for Inventories and (1,610) million yen for others.
- 3. Adjustment to segment assets, which amounted to 96,963 million yen, mainly includes investments in "Cash and deposit", "Investments securities", "Deferred tax assets" and assets of the Administrative Department.

53,045

17,183

402,294

144,824

(Supplementary Information)

[Geographic Segments]

Tangible noncurrent assets

(Millions of yen)

For the year ended

March 31, 2013

Japan Europe Americas Asia and others Total

75,394

9,240

87,940

19,125

185,913

99,275

(2) Fiscal year ended March 31, 2014 (Millions of yen)

	For the year ended March 31, 2014							
	Japan	Europe	Americas	Asia and others	Total			
Sales	189,041	96,892	110,972	70,452	467,359			
Tangible noncurrent assets	105,400	10,712	17,722	23,919	157,755			

[Impairment Loss on Tangible noncurrent assets]

(1) Fiscal year ended March 31, 2013

Not applicable.

(2) Fiscal year ended March 31, 2014 (Millions of yen) For the year ended March 31, 2014 Blood Cardiac & General Hospital VascularManagement Subtotal Business Business Business Company Total Impairment Loss 3,454 7,594 1,965 13,014 2,336 15,351